• Investors may be wondering whether CONMED at around US$38.10 is starting to offer value, or if the stock’s long slide still reflects unresolved risks.
• The share price recently closed at US$38.10, with a 3.9% move over 7 days and 10.3% over 30 days, against a year to date return of a 6.0% decline and a 1 year return of a 33.5% decline that sits on top of a 68.0% decline over 3 years and a 71.8% decline over 5 years.
• Those long term returns have sharpened focus on how investors are assessing CONMED’s prospects. Recent news coverage has centered on whether the current price now reflects a more cautious view of the business. For readers, that sets the scene for asking whether the stock is now simply out of favour or if the re rating is tied to more fundamental concerns.
• On Simply Wall St’s 6 point valuation framework, CONMED records a value score of 5. The rest of this article will break down how different valuation approaches assess that score and why an even richer way of thinking about value is worth keeping in mind by the end.

Approach 1: CONMED Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today’s dollars. It asks what all of CONMED’s future cash generation is worth in present value terms.

For CONMED, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month Free Cash Flow is reported at about $125.1 million. Analyst estimates and extrapolations then project Free Cash Flow out over ten years, with figures such as $194.7 million in 2026 and $166.5 million in 2035. Each year is discounted back to today using a required return.

Adding those discounted cash flows together, plus a terminal value, gives an estimated intrinsic value of about $78.83 per share. Against the recent share price of about $38.10, this implies an intrinsic discount of roughly 51.7%, which indicates the stock is trading well below this DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests CONMED is undervalued by 51.7%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: CONMED Price vs Earnings

For profitable companies, the P/E ratio is a useful cross check because it links what you pay for the stock to what the business is currently earning per share. It effectively tells you how many years of current earnings the market is pricing in.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected earnings growth or lower perceived risk can justify a higher P/E, while lower growth or higher risk usually supports a lower P/E.

CONMED currently trades on a P/E of 20.9x. This sits below the Medical Equipment industry average of 24.1x and well below the peer group average of 60.8x. Simply Wall St’s Fair Ratio for CONMED is 28.4x. This is a proprietary estimate of the P/E investors might typically pay given factors such as earnings growth profile, industry, profit margins, market cap and risk characteristics.

The Fair Ratio is more tailored than a simple comparison to peers or the industry because it adjusts for those company specific factors rather than assuming all stocks deserve the same multiple. With CONMED’s actual P/E of 20.9x sitting below the Fair Ratio of 28.4x, this framework suggests the stock is trading at a discount on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your CONMED Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story to your numbers by linking your view of CONMED’s business to explicit forecasts for revenue, earnings and margins. This translates into a Fair Value you can compare with the current share price, updates automatically as new news or earnings are added, and makes it easy to see how one investor might justify a Fair Value of US$52.00 while another lands closer to US$39.00 based on different assumptions about execution, risks and the P/E that feels reasonable to them.

Do you think there's more to the story for CONMED? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.